Skip to Content

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

Acalabrutinib, a second-generation, covalent Bruton tyrosine kinase inhibitor, demonstrated progression-free survival benefit and/or favorable tolerability vs comparators in patients with treatment-naive and relapsed/refractory CLL. This study assesses the impact of dose modifications or discontinuations that occur in the first year of acalabrutinib in treatment-naive patients on overall survival (OS), in patients with treatment-naive CLL, and in patients with relapsed/refractory CLL. In this MEDtalk, Alessandra Tedeschi presents the results.

Alessandra Tedeschi

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top